Search

Displaying results 7331 - 7340 of 10000 in total
  1. Drug

    Linarotene

    go.drugbank.com/drugs/DB21165
    Experimental

    The usage of the INN stem '-arotene' in the name indicates that Linarotene is a arotinoid derivative. Linarotene has a monoisotopic molecular weight of 398.2 Da.

  2. Drug

    BMS-817399

    go.drugbank.com/drugs/DB14941
    Investigational

    BMS-817399 is under investigation in clinical trial NCT01404585 (Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis).

  3. Drug

    PA-1050040

    go.drugbank.com/drugs/DB06039
    Experimental

    It inhibits virus replication by the same mechanism of action as BVM.

  4. Drug

    Psilocybin

    go.drugbank.com/drugs/DB11664
    Investigational

    Psilocybin has been investigated for the treatment of Anxiety and Stage IV Melanoma. In November, 2019, it was granted Breakthrough Therapy status by the FDA.

  5. Drug

    mRNA-3351

    go.drugbank.com/drugs/DB17718
    Experimental

    mRNA-3351 is a modified mRNA encoding the UGT1A1 gene. Developed by Moderna, it is currently being investigated as the treatment for Crigler-Najjar syndrome

  6. Drug

    Tiropramide

    go.drugbank.com/drugs/DB13091
    Investigational

    Tiropramide is under investigation in clinical trial NCT01629212 (Comparison of the Efficacy and Safety of Tiropramide and Octylonium in the Treatment of Irritable Bowel Syndrome).

  7. Drug

    Clenoliximab

    go.drugbank.com/drugs/DB06241
    Experimental

    It has investigated for the treatment of rheumatoid arthritis.

  8. Drug

    Cloprednol

    go.drugbank.com/drugs/DB13843
    Investigational

    Cloprednol is a synthetic glucocorticoid that has been investigated for use in the treatment of asthma. [A31775,A31776]

  9. Drug

    Dutogliptin

    go.drugbank.com/drugs/DB11723
    Investigational

    Dutogliptin has been investigated for the treatment of Diabetes Mellitus, Type II.

  10. Drug

    DDP-200

    go.drugbank.com/drugs/DB05919
    Experimental

    DDP200 is developed by Dynogen for the treatment of non-incontinent form of overactive bladder (OAB) with particular focus on both male and female patients with urinary frequency, urinary urgency and nocturia